CA2841158A1 - Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes - Google Patents

Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes Download PDF

Info

Publication number
CA2841158A1
CA2841158A1 CA2841158A CA2841158A CA2841158A1 CA 2841158 A1 CA2841158 A1 CA 2841158A1 CA 2841158 A CA2841158 A CA 2841158A CA 2841158 A CA2841158 A CA 2841158A CA 2841158 A1 CA2841158 A1 CA 2841158A1
Authority
CA
Canada
Prior art keywords
expression
rhoa
subject
microrna
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2841158A
Other languages
English (en)
Inventor
Yihong Yao
Nan Shen
Wei Fan
Yuanjia Tang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHANGHAI RENJI HOSPITAL
MedImmune LLC
Original Assignee
SHANGHAI RENJI HOSPITAL
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHANGHAI RENJI HOSPITAL, MedImmune LLC filed Critical SHANGHAI RENJI HOSPITAL
Publication of CA2841158A1 publication Critical patent/CA2841158A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2841158A 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes Abandoned CA2841158A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161501482P 2011-06-27 2011-06-27
US61/501,482 2011-06-27
PCT/US2012/044197 WO2013003346A2 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procédés d'utilisation dans des maladies auto-immunes

Publications (1)

Publication Number Publication Date
CA2841158A1 true CA2841158A1 (fr) 2013-01-03

Family

ID=47424764

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2841158A Abandoned CA2841158A1 (fr) 2011-06-27 2012-06-26 Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes

Country Status (8)

Country Link
EP (1) EP2723349A4 (fr)
JP (1) JP2014521600A (fr)
KR (1) KR20140066671A (fr)
AU (1) AU2012275552A1 (fr)
BR (1) BR112013033794A2 (fr)
CA (1) CA2841158A1 (fr)
RU (1) RU2014102217A (fr)
WO (1) WO2013003346A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112843233A (zh) * 2019-11-26 2021-05-28 中国科学院上海营养与健康研究所 预防皮肤衰老与早衰的内源性小rna分子标靶及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1432724A4 (fr) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc Inhibition a mediation par interference d'arn de genes de map kinase
CN101376910B (zh) * 2007-08-27 2012-01-11 中国科学院上海生命科学研究院 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
WO2010065961A2 (fr) * 2008-12-05 2010-06-10 Whitehead Institute For Biomedical Research Compositions et procédés concernant le mir-31

Also Published As

Publication number Publication date
BR112013033794A2 (pt) 2019-09-24
KR20140066671A (ko) 2014-06-02
WO2013003346A2 (fr) 2013-01-03
EP2723349A2 (fr) 2014-04-30
WO2013003346A3 (fr) 2013-02-28
JP2014521600A (ja) 2014-08-28
EP2723349A4 (fr) 2015-01-14
RU2014102217A (ru) 2015-08-10
AU2012275552A1 (en) 2014-02-06

Similar Documents

Publication Publication Date Title
EP2352830B1 (fr) Traitement de maladies liées à l'apolipoprotéine a1 par l'inhibition d'un produit de la transcription antisens naturel de l'apolipoprotéine a1
ES2760912T3 (es) Tratamiento de enfermedades relacionadas con la Sirtuina 1 (SIRT1) por inhibición del transcrito antisentido natural de la Sirtuina 1
ES2727582T3 (es) Sistema para la utilización de energía de condensado
EP2111449B1 (fr) Agents nucléotidiques de silençage de h19 destinés au traitement de l'arthrite rhumatoïde
CA2599524C (fr) Matieres et procedes destines au traitement de maladies allergiques
MX2011005910A (es) Tratamiento de enfermedades relacionadas con eritropoyetina (epo) mediante inhibicion del transcrito antisentido natural a eritropoyetina.
US9789132B2 (en) Methods targeting miR-128 for regulating cholesterol/lipid metabolism
CN101376910B (zh) 微小rna基因在系统性红斑狼疮疾病诊断和治疗中的作用
WO2012121178A1 (fr) Inhibiteur d'angiogenèse tumorale
Tu et al. MicroRNA-10b promotes arthritis development by disrupting CD4+ T cell subtypes
EP2501814A1 (fr) Inhibiteurs de concentration centrosomale
CA2841158A1 (fr) Compositions de microarn-31 et leurs procedes d'utilisation dans des maladies auto-immunes
KR20190079558A (ko) miR-204 억제제의 골관절염 치료 용도
Baharlooi et al. Nucleic acids as novel therapeutic modalities to address multiple sclerosis onset and progression
WO2021030867A1 (fr) Méthode de modulation de l'adiposité
US20040110698A1 (en) Oligonucleotides and methods using same for treating cox-ll associated diseases
WO2014106012A1 (fr) Procédés de modulation de prolifération et leurs utilisations

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20170627